In September, for example, England’s High Court concluded that it is lawful to use Avastin in place of Lucentis and another VEGF drug, Bayer’s Eylea (aflibercept). Novartis and Roche launched ...

Avastin needs to be diluted and repackaged before ... Meanwhile, patents on both Lucentis and Eylea are due to expire in the US in 2020, raising the prospect of additional low-cost biosimilar ...

At a pre-specified interim analysis of Merck’s phase 3 Keynote-B96 trial, which is testing Keytruda plus chemotherapy with or without Roche’s Avastin in patients with platinum-resistant ...

The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL ...

Morris came out as bisexual in June of last year Gary Gershoff/Getty Men are from Mars and women are from Venus — and Maren Morris agrees! In a recent appearance on the U Up? podcast, the ...

In April this year, the company also submitted an application for a third indication of Eylea™ 8 mg with the European Medicines Agency. It is likely that the medicine used to treat patients with ...

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea ...

Jake Rosen is a reporter covering the Department of Justice. He was previously a campaign digital reporter covering President Trump's 2024 campaign and also served as an associate producer for ...

Are the New York Knicks on the verge of collapse? The Knicks, despite gritty play from their Villanova core of Jalen Brunson, Josh Hart, and Mikal Bridges, are in a dangerous position to lose ...

Leafs Nation, the hard part is almost over. You’ve waited 375 days for this. Tonight, you’ll find out whether this year’s team has what it takes to contend for hockey’s ultimate prize. The ...

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea ...